IQVIA (IQV) Set to Announce Earnings on Thursday

IQVIA (NYSE:IQV) will release its earnings data before the market opens on Thursday, May 2nd. Analysts expect IQVIA to post earnings of $2.19 per share for the quarter. IQVIA has set its FY24 guidance at $10.95-11.25 EPS and its FY 2024 guidance at 10.950-11.250 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. During the same period in the prior year, the company earned $2.54 earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, analysts expect IQVIA to post $10 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Stock Performance

Shares of NYSE IQV opened at $240.84 on Thursday. The stock has a 50 day moving average price of $245.50 and a 200 day moving average price of $222.69. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. The stock has a market capitalization of $43.71 billion, a PE ratio of 33.04, a price-to-earnings-growth ratio of 2.24 and a beta of 1.50.

Insider Activity

In other news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the sale, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,285 shares of company stock worth $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent research reports. Robert W. Baird raised their price objective on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. Barclays raised their price objective on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Evercore ISI raised their price objective on IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 15th. Truist Financial raised their price objective on IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.